Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could This Vaccine Become Sanofi's Latest Blockbuster?

TheMotleyFool

0 0

Could This Vaccine Become Sanofi's Latest Blockbuster?: https://g.foolcdn.com/editorial/images/718206/a-patient-attends-a-doctor-appointment.jpg

Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants.

Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year. How much of a lift in sales could this product provide for Sanofi?

Let's explore the phase 3 clinical trial results of the vaccine and the global RSV vaccine market to answer this question.

Source Fool.com

Like: 0

SNY

Share